Treatment
Aflibercept clinical trials
We’re tracking 34 recruiting studies that include Aflibercept, each written for real people, not researchers, below.
Recruiting studies
- NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT07389980RecruitingPhase 3
Personalized high-dose aflibercept for a type of wet AMD
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
DaeguAges 19 years+ - NCT07338097Enrolling by invitation
Comparing two eye injections for diabetic macular edema
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
Multan, Punjab ProvinceAges 30–60 - NCT07489131RecruitingPhase 3
Comparing a new macular edema treatment to Eylea HD
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
BudapestAges 18 years+ - NCT06850571RecruitingPhase 4
Comparing two eye injections for diabetic macular edema
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
BaghdadAges 40 years+ - NCT06662994RecruitingPhase 4
High dose aflibercept for diabetic macular edema after vitrectomy
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
Fullerton, CaliforniaAges 21 years+ - NCT07640997Recruiting
Real-world study of aflibercept for age-related macular degeneration
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Beijing, Beijing MunicipalityAges 50 years+ - NCT06315556Recruiting
Study of Eylea for preterm babies with retinopathy of prematurity in the UK
This study collects information on how the medicine Eylea is given to preterm babies with retinopathy of prematurity (an eye problem in premature infants) using a special dosing device. The goal is to see how the treatment works in everyday hospital care.
Multiple LocationsAges Up to 1 year - NCT04519619Recruiting
Safety study of aflibercept eye injections in Japanese glaucoma patients
This trial checks how safe aflibercept (eye injection) is for Japanese people with neovascular glaucoma. You may be able to join if you already received aflibercept treatment under the approved Japanese instructions and have the correct diagnosis.
Multiple LocationsAges Any age - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+ - NCT02669953Recruiting
Aflibercept injections for persistent wet macular degeneration
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
ViennaAges 50 years+ - NCT07734844RecruitingPhase 3
New vs existing treatment for diabetic macular edema
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
Glendale, CaliforniaAges 18 years+ - NCT07705607RecruitingPhase 3
Comparing MK-8748 to standard treatment for diabetic eye swelling
This trial tests a new medicine (MK-8748) against an existing treatment (aflibercept) for people with diabetic macular edema, which causes vision loss due to swelling in the back of the eye. The goal is to see which works better to improve or protect vision.
Winter Haven, FloridaAges 18 years+ - NCT07705555RecruitingPhase 3
Comparing a new eye injection to standard treatment for diabetic eye swelling
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
Glendale, CaliforniaAges 18 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Scottsdale, ArizonaAges 50 years+ - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06942520RecruitingPhase 2
Gene therapy for diabetic macular edema in adults
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
Reno, NevadaAges 25–89 - NCT06929507Recruiting
Faricimab eye injections and kidney function in diabetes
This trial tests whether faricimab, an eye injection for certain eye conditions, affects kidney function in people with diabetes. It is for those with diabetic macular edema, wet age-related macular degeneration, or macular edema from a vein blockage, who are already taking kidney-protective medications.
Alexandroupoli, EvrosAges Any age - NCT06893965Recruiting
Eye pressure check after Eylea 8mg injection
This trial measures eye pressure right after an injection of a higher-dose Eylea (aflibercept 8mg) to see how it affects the eye. It may help people who need frequent anti-VEGF shots for conditions like wet AMD or diabetic eye disease.
Toulon, VarAges 18 years+ - NCT06610747Recruiting
Home versus hospital care for diabetic eye swelling
This study tests whether receiving anti-VEGF injections for diabetic macular edema (DME) at home is as safe and effective as getting them in the hospital. You would use a home device to check your vision and eye scans, and a nurse would visit for injections.
Dongguan, GuangdongAges 18 years+ - NCT06271330Recruiting
Switching older injections to faricimab for wet AMD
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Nantes, NantesAges 18 years+
What Aflibercept is being studied for
Conditions with recruiting Aflibercept studies.
Common questions
- Are there clinical trials studying Aflibercept?
- Yes. Clin2 currently lists 34 recruiting studies that include Aflibercept, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Aflibercept trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Aflibercept an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Aflibercept or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.